Global News Roundup – Germany and Spain Market Updates
Global News Roundup – Germany and Spain Market Updates - September 2026
September 2026
Germany update
DE Reform Overview
Germany’s 2026 GKV reform substantially increases mandatory manufacturer rebates beginning in 2027, while the scope of a broader localisation-based exemption remains under development
The statutory manufacturer rebate will increase from 7% to 15.5% beginning on 1 January 2027 for eligible patent-protected medicines[i]; the proposed expenditure-linked dynamic rebate was dropped in favour of a higher fixed rate, providing greater predictability but materially increasing the baseline deduction from manufacturer revenues[ii]
The higher rebate is additive to, rather than a replacement for, AMNOG price negotiation – manufacturers will therefore face the 15.5% statutory deduction on the relevant reimbursement amount irrespective of the G-BA added-benefit outcome[iii]
The government is developing a “Standortklausel” that could exempt qualifying manufacturers / products from the incremental 8.5pp rebate, linking pharmaceutical investment and employment in Germany to relief from the additional pricing pressure; however, precise eligibility criteria remain under development[iv]
The reform reinforces broader cost-containment measures, including strengthened price-volume controls; for vaccines, the supplementary rebate will increase to 9%, alongside a price moratorium for patent-protected immunisation vaccines from 2027-2030[v]
Implications for Manufacturers
The reform creates a potentially quantifiable value for German localisation, but the strategic case will depend heavily on portfolio exposure and final exemption criteria
Realised German net revenues will face downward pressure in 2027 absent an exemption, widening the gap between the AMNOG-negotiated reimbursement amount and manufacturer revenue and requiring the 15.5% rebate to be incorporated into future German forecasts
The Standortklausel could make German footprint a direct P&MA consideration: Avoiding the incremental 8.5pp rebate would create a quantifiable economic benefit from qualifying German investment, rather than localisation being primarily an industrial-policy consideration
The investment case will be portfolio-dependent: Manufacturers with larger eligible German revenues stand to avoid a greater absolute rebate and may therefore have a stronger rationale for incremental local investment; the benefit is likely to be considerably smaller for low-volume portfolios
Manufacturers should currently treat the Standortklausel as upside rather than base case: The 15.5% rebate is established, while the activities and thresholds required to qualify for an exemption remain under development; once clarified, manufacturers should assess the portfolio-level rebate avoided vs. incremental cost of qualifying German investment
Spain update
Spain Reform Overview
Spain is moving towards a more formal, evidence-led pricing and reimbursement (P&R) framework, with the new HTA Royal Decree complemented by broader pricing, funding and confidentiality reforms
The Royal Decree 415/2026 establishes Spain’s new national HTA framework, aligning with the EU HTA Regulation and creating a more structured evidence assessment process to support future P&MA decisionsvi
Where available, the EU JCA will feed directly into Spanish HTAvi avoiding duplication of clinical assessment, alongside a broader non-clinical assessment at national level, covering economic, ethical, organisational, social and legal considerations; detailed methodologies are still pending, but RWE, patient-relevant / QoL evidence, and CE will be consideredvi
The decree formalizes HTA timelines, manufacturer engagement and transparencyvi:
- The clinical assessment and the non-clinical assessment are completed within 70 days each; where appliable, clinical report must be completed within 15 days of publication of the JCA report
- Manufacturers have up to 10 days to comment on draft reports before finalisation, and will be required to disclose development and production costs, and public / non-profit funding sources for the economic evaluation
A separate draft pricing and reimbursement (P&R) Royal Decree is intended to complement the new HTA framework, linking technical evaluation with P&R decisions and providing a framework for managed access and contracting mechanisms (incl. conditional / provisional reimbursements, expenditure caps, price-volume and outcome-based agreements)vii,viii
A new confidentiality amendment to the medicines law under Law 3/2026 aims to strengthen the legal protection for pricing and funding agreements while increasing government visibility into these arrangementsix
Implications for Manufacturers
The emerging framework is likely to increase the importance of coordinated EU evidence planning, local economic evidence and flexible contracting in Spanish market access strategy
Greater importance of JCA preparation: JCA evidence will increasingly shape Spanish access strategy, and manufacturers will need to complement this with local non-clinical evidence (e.g., CEA, budget impact and RWE)
Contracting strategy could become increasingly important: If draft P&R decree is implemented, ES could make greater use of MEAs and contracting to address concerns around affordability and BI, while maintaining separate public list prices for IRP purposes
Post-launch evidence requirements could become more prominent: The emerging framework supports reassessment, real-world data collection and financing arrangements linked to evidence generation and outcomes
Abbreviations:
AMNOG = Arzneimittelmarkt-Neuordnungsgesetz; BI = budget impact; CEA = cost-effectiveness analysis; DE = Germany; ES = Spain; EU = European Union; G-BA = Gemeinsamer Bundesausschuss; GKV = statutory health insurance (Gesetzliche Krankenversicherung); HTA = health technology assessment; IRP = international reference pricing; JCA = joint clinical assessment; P&MA = pricing and market access; P&R = pricing and reimbursement; pp = percentage points; QoL = quality of life; RWE = real-world evidence; MEA = managed entry agreement
Sources:
Germany Update:
[i] Bundesministerium für Gesundheit (BMG). Bundestag beschließt GKV-Beitragssatzstabilisierungsgesetz. Berlin: BMG; 10 July 2026. https://www.bundesgesundheitsministerium.de/presse/pressemitteilungen/bundestag-beschliesst-gkv-beitragssatzstabilisierunggesetz-pm-10-07-2026
[ii] Bundesministerium der Justiz / Bundesamt für Justiz. Sozialgesetzbuch (SGB) Fünftes Buch (V), § 130a Rabatte der pharmazeutischen Unternehmer. Current version, accessed 23 September 2026. https://www.gesetze-im-internet.de/sgb_5/__130a.html
[iii] Bundesministerium für Wirtschaft und Energie (BMWE) and Bundesministerium für Gesundheit (BMG). Pharmastandort Deutschland: Neues Fachgremium nimmt Arbeit auf. Berlin; 28 August 2026. https://www.bundeswirtschaftsministerium.de/Redaktion/DE/Pressemitteilungen/2026/08/20260828-pharmastandort-deutschland-fachgremium.html
[iv] Bundesministerium der Justiz / Bundesamt für Justiz. Sozialgesetzbuch (SGB) Fünftes Buch (V), § 130b – Vereinbarungen zwischen dem Spitzenverband Bund der Krankenkassen und pharmazeutischen Unternehmern über Erstattungsbeträge für Arzneimittel. Current version, accessed 23 September 2026. https://www.gesetze-im-internet.de/sgb_5/__130b.html1
[v] Bundesministerium für Gesundheit (BMG). Bundestag beschließt GKV-Beitragssatzstabilisierungsgesetz. 10 July 2026. https://www.bundesgesundheitsministerium.de/presse/pressemitteilungen/bundestag-beschliesst-gkv-beitragssatzstabilisierunggesetz-pm-10-07-2026
vi Agencia Estatal Boletín Oficial del Estado. Real Decreto 415/2026, de 27 de mayo, por el que se regula la evaluación de tecnologías sanitarias. BOE núm. 131, 29 May 2026.
https://www.boe.es/eli/es/rd/2026/05/27/415/con
vii Ministerio de Sanidad. Sanidad abre a audiencia pública el real decreto que culmina la reforma farmacéutica de la legislatura. 19 June 2026.
https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=6943&metodo=detalle
viii Ministerio de Sanidad. Proyecto de Real Decreto por el que se regula el procedimiento de financiación y fijación de precios de los medicamentos en el Sistema Nacional de Salud. Text submitted to public consultation, 19 June 2026.
ix Agencia Estatal Boletín Oficial del Estado. Ley 3/2026, de 29 de julio, de modificación de normas sobre el programa de cribado neonatal del Sistema Nacional de Salud y de otra normativa. BOE núm. 186, 31 July 2026; entry into force 1 August 2026
inisterio de Sanidad. Proyecto de Real Decreto por el que se regula el procedimiento de financiación y fijación de precios de los medicamentos en el Sistema Nacional de Salud. Text submitted to public consultation, 19 June 2026.
https://www.boe.es/eli/es/l/2026/07/29/3/con
Spain update:
vii Ministerio de Sanidad. Sanidad abre a audiencia pública el real decreto que culmina la reforma farmacéutica de la legislatura. 19 June 2026.
https://www.sanidad.gob.es/gabinete/notasPrensa.do?id=6943&metodo=detalle
viii Ministerio de Sanidad. Proyecto de Real Decreto por el que se regula el procedimiento de financiación y fijación de precios de los medicamentos en el Sistema Nacional de Salud. Text submitted to public consultation, 19 June 2026.
ix Agencia Estatal Boletín Oficial del Estado. Ley 3/2026, de 29 de julio, de modificación de normas sobre el programa de cribado neonatal del Sistema Nacional de Salud y de otra normativa. BOE núm. 186, 31 July 2026; entry into force 1 August 2026
inisterio de Sanidad. Proyecto de Real Decreto por el que se regula el procedimiento de financiación y fijación de precios de los medicamentos en el Sistema Nacional de Salud. Text submitted to public consultation, 19 June 2026.
https://www.boe.es/eli/es/l/2026/07/29/3/con